Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?

Takeda Pharmaceutical’s Takecab (vonoprazan) made its Japan debut on February 26 as a new treatment for acid-related diseases. While proton pump inhibitors (PPIs) are widely used nowadays in first-line treatment for gastric ulcer and gastroesophageal reflux disease (GERD), Takecab belongs...read more